Abstract
Background Patients with acute decompensation (AD) of cirrhosis are at high risk of developing acute-on-chronic liver failure (ACLF), a syndrome characterized by multiple organ failure and high short-term mortality. This study aimed to analyse alterations in peripheral blood mononuclear cells (PBMCs) in patients with AD using single-cell technologies and to explore their implications for risk stratification and prognosis.
Methods A total of 63 AD patients and 15 healthy donors were enrolled at five European centers, with blood samples collected upon hospital admission. Patients were monitored for 90 days after study inclusion, focusing on hospital readmission related to AD and the development of ACLF. Cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) was performed on PBMCs from 16 patients (n=6 without readmission, n=6 with readmission, and n=4 with ACLF development) along with 4 healthy controls. The whole blood of the same 16 patients was assessed by bulk RNA-seq. The whole blood transcriptional profiles from two independent prospective multicentre cohorts of patients with AD (PREDICT (n=689) and ACLARA (n=521)) were included as validation cohorts.
Results Cell proportion analysis revealed a significant increase of classical monocytes in patients with subsequent ACLF development. Notably, classical monocytes represented the cell type with the highest transcriptional alterations. Within the classical monocyte population, a specific subcluster, termed “C2”, was identified and found to be enriched during progression towards ACLF. This monocytic subpopulation was primarily characterized by decreased expression of genes encoding enzymes relevant to cellular energy supply, such as oxidative phosphorylation and ATP production. Pathway analysis confirmed a marked impairment of energy metabolism pathways within the C2 subcluster. A gene signature derived from that monocytic subpopulation was significantly increased in patients with bacterial infection, ACLF development and non-survivors of two independent multicenter cohorts of patients with AD.
Conclusion Patients with acute decompensation of cirrhosis who subsequently develop ACLF are characterized by a subpopulation of classical monocytes exhibiting features of impaired energy metabolism pathways.
Competing Interest Statement
Jonel Trebicka has received speaking and/or consulting fees from Astra-Zeneca, Gore, Boehringer-Ingelheim, Falk, Grifols, Genfit, and CSL Behring. T Bruns received consulting fees from Intercept/Advanz Pharma, Grifols, Sobi, and SmartDyeLivery. Paolo Caraceni has received speaking and/or consulting fees from Grifols SA , Octapharma SA, CSL Behring, and Gilead.
Funding Statement
This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 847949. This research was made possible through access to data generated by the PREDICT and ACLARA studies promoted and funded by the European Foundation for the Study of Chronic Liver Failure (EF-CLIF), a private, non-profit organization supported by unrestricted grants from Grifols and Genfit. T.H.W. received financing from the START program of the RWTH Aachen University. N.P.P. was funded by a Ramon y Cajal fellow (RYC2021‐032197‐I) from the MCIN/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR and by a Juan de la Cierva-formacion fellow (FJC2019-042304-I) from the Spanish Ministry of Science and Innovation (MCIN). T.B. was supported by the German Research Foundation (SFB1383 Project ID 403224013/B07). The Genome Analysis Platform in CIC bioGUNE is supported by the Basque Department of Industry, Tourism and Trade (Etortek, Elkartek and Emaitek Programs), the Innovation Technology Department of Bizkaia County, CIBERehd Network, and Spanish MINECO the Severo Ochoa Excellence Accreditation (CEX2021-001136-S). JC laboratory is supported by Ministerio de Ciencia e Innovacion/Agencia Estatal Investigacion MCIN/AEI (PID2022-138970OB-I00 10.13039/501100011033/FEDER, UE). C.T. was supported by the DFG grants TR285/10-2 and SFB CRC1382, A08 (ID 403224013). PER research laboratory is supported by the Fondation pour la Recherche Medicale (FRM EQU202303016287), Institut National de la Sante et de la Recherche Medicale (ATIP AVENIR), the Agence Nationale pour la Recherche (ANR-18-CE14-0006-01, RHU QUID-NASH, ANR-18-IDEX-0001, ANR-22-CE14-0002) by Emergence, Ville de Paris, by Fondation ARC and by France 2030 RHU LIVER-TRACK (ANR-23-RHUS-0014). D.G.-C. research laboratory is supported by King Abdullah University of Science and Technology.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the local ethics committee of each participating center (Hôpital Beaujon, Université Paris-Cité, France; Goethe University Frankfurt, Germany; RWTH Aachen University, Germany; University of Bologna, Italy; University of Turin, Italy) and conducted in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Single-cell data produced in the present study are available upon reasonable request to the authors. A submission to the European Genome-phenome Archive (EGA) is under progress. Bulk RNA-seq data used in the present study are available upon reasonable request to the authors.
